4/15
01:21 pm
pdsb
PDS Biotechnology (PDSB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
PDS Biotechnology (PDSB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
4/15
08:45 am
pdsb
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
High
Report
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
4/4
01:04 am
pdsb
High
Report
3/30
09:11 pm
pdsb
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ... [Yahoo! Finance]
Medium
Report
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ... [Yahoo! Finance]
3/30
07:15 am
pdsb
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement [Yahoo! Finance]
Medium
Report
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement [Yahoo! Finance]
3/30
07:00 am
pdsb
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Medium
Report
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
3/29
05:39 pm
pdsb
PDS Biotechnology FY 2025 Earnings Preview [Seeking Alpha]
High
Report
PDS Biotechnology FY 2025 Earnings Preview [Seeking Alpha]
3/24
04:05 pm
pdsb
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
Medium
Report
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
2/20
08:30 am
pdsb
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Medium
Report
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
1/28
08:45 am
pdsb
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
Medium
Report
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
1/22
09:15 am
pdsb
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
Low
Report
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
1/22
08:45 am
pdsb
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Low
Report
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101